Anticoagulant
Heparin
Also called UFH
Watch the explainer
Heparin vs Warfarin: aPTT vs INR, HIT, Bridging, Antidotes and DOAC Reversal
Indications
- DVT and PE, especially with instability or CrCl under 30 (AHA/ACC 2026 prefers LMWH even when lysis or a procedure may follow)
- VTE prophylaxis (subcutaneous), including in severe kidney failure
- Acute coronary syndromes and PCI (off-label)
- Anticoagulation of bypass, ECMO, CRRT and dialysis circuits
- Atrial fibrillation with embolization; peripheral arterial embolism
- DIC in which thrombosis predominates
Dosing
| Where | Dose |
|---|---|
| Daily ICU prophylaxis | Heparin (UFH) SC: 5,000 units every 8–12 h; for severe kidney failure or when a procedure is near |
Mechanism of action
Heparin acts through antithrombin, a serine protease inhibitor. A pentasaccharide on about one-third of heparin chains binds antithrombin and bends its reactive loop, speeding protease inhibition about 1,000-fold. That shape change alone blocks factor Xa, but blocking thrombin needs a chain of at least 18 saccharides to bridge antithrombin and thrombin; heparin then lets go and is reused. Fibrin-bound thrombin and Xa in prothrombinase are shielded, so heparin stops clot growth without dissolving clot.
Pharmacology
- Hematologic: inhibits Xa and thrombin equally (1:1), plus IXa, XIa and XIIa; prolongs the aPTT, ACT and thrombin time
- Hematologic: chains of about 12 or more saccharides bind platelet factor 4, forming the complexes behind HIT
- Metabolic: releases lipoprotein lipase (triglycerides fall, then rebound when heparin stops); suppresses aldosterone, so potassium can rise
- Other: osteoporosis after months of use; transaminases often rise without liver injury
Pharmacokinetics
| Onset | IV immediate; SC slower and variable |
|---|---|
| Peak | SC 2–4 h |
| Duration | Hours; stop 4–6 h before procedures |
| Half-life | Dose-dependent: about 30 min after 25 units/kg, 60 min after 100 and 150 min after 400 (ACCP 2012) |
| Distribution | Vd 0.07 L/kg (plasma volume); does not cross the placenta |
| Protein binding | Extensive and variable (fibrinogen, lipoproteins, PF4), so the dose response is unpredictable |
| Metabolism | Endothelial cells and macrophages take up and depolymerize it: fast but saturable |
| Elimination | Renal, a slower route that dominates once the cellular route saturates; little change in kidney failure |
| Routes | IV or deep SC (reduced bioavailability); avoid IM |
Chemistry
- A densely sulfated glycosaminoglycan (iduronic acid and glucosamine units), the most negatively charged natural molecule: fully ionized, water-soluble, not absorbed orally
- Chains of 3,000–30,000 Da (mean 15,000, about 45 saccharides); the antithrombin-binding pentasaccharide needs a rare 3-O-sulfated glucosamine
- Extracted from porcine intestinal mucosa, the only US source since the 1990s: contraindicated in pork allergy, and some patients decline it on religious grounds
- Vials of 1,000–20,000 units/mL (pH 5.0–7.5), some preserved with benzyl alcohol (avoid in neonates); premixed dextrose bags contain sodium metabisulfite (sulfite allergy)
Adverse effects and cautions
In the one-pagers
- Bleeding, Reversal, HIT and DICReversing anticoagulants in major bleeding: Unfractionated heparin: Protamine 1 mg per 100 units given in last 2–3 h (max 50 mg): Fast; watch for hypotension, anaphylaxis
- Pulmonary EmbolismDiagnosis: unstable vs stable: Shock or hypotension: Heparin now; bedside echo or CTPA, whichever is faster
- CRRT (Continuous Renal Replacement)Anticoagulation: KDIGO suggests regional citrate over heparin when citrate is safe: longer filter life, less bleeding.
- Impella Heart PumpPurge system: Add heparin 25 or 50 units/mL, or bicarbonate 25 or 50 mEq/L if heparin is contraindicated. Never both; no other anticoagulant.
- Peripheral Vascular EmergenciesAcute limb ischemia: Notify the provider at once; expect IV heparin on diagnosis and emergency vascular review
- ECMO EssentialsMonitoring and anticoagulation: Anti-Xa on UFH: 0.3–0.7 IU/mL
In the algorithms
- New Fever in the ICU
- STEMI
- Massive Hemoptysis
- Massive Pulmonary Embolism
- Accidental Hypothermia
- CRRT Pressure Alarms
Other anticoagulant drugs
Sources
- FDA label: Heparin Sodium, Fresenius Kabi (2021)
- Garcia, ACCP Parenteral Anticoagulants (Chest 2012)
- ASH HIT guideline (2018)
For education and exam preparation only. Follow your institution’s protocols. Typical adult values for study. Follow the order, the label and your institution's protocols.